We are live on ! Find out more
ABMD

Abiomed Inc

Delisted

ABMD was delisted on the 21st of December, 2022.

529 hedge funds and large institutions have $17.9B invested in Abiomed Inc in 2018 Q3 according to their latest regulatory filings, with 71 funds opening new positions, 202 increasing their positions, 184 reducing their positions, and 63 closing their positions.

New
Increased
Maintained
Reduced
Closed

13% more first-time investments, than exits

New positions opened: 71 | Existing positions closed: 63

12% more capital invested

Capital invested by funds: $16B → $17.9B (+$1.93B)

10% more repeat investments, than reductions

Existing positions increased: 202 | Existing positions reduced: 184

0% more funds holding

Funds holding: 527529 (+2)

5% less funds holding in top 10

Funds holding in top 10: 2120 (-1)

41% less call options, than puts

Call options by funds: $251M | Put options by funds: $424M

Holders
529
Holders Change
+2
Holders Change %
+0.38%
% of All Funds
12.09%
Holding in Top 10
20
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-4.76%
% of All Funds
0.46%
New
71
Increased
202
Reduced
184
Closed
63
Calls
$251M
Puts
$424M
Net Calls
-$173M
Net Calls Change
-$128M
Name Holding Trade Value Shares
Change
Change in
Stake
JP Morgan Chase
26
JP Morgan Chase
New York
$164M +$9.67M +24,531 +7%
American Century Companies
27
American Century Companies
Missouri
$148M -$28.6M -72,514 -18%
CTA
28
Carillon Tower Advisers
Florida
$135M -$36.4M -92,344 -23%
EAM
29
Eagle Asset Management
Florida
$128M +$8.27M +20,968 +8%
William Blair Investment Management
30
William Blair Investment Management
Illinois
$120M -$6.35M -16,097 -6%
New York State Common Retirement Fund
31
New York State Common Retirement Fund
New York
$114M -$5.45M -13,828 -5%
William Blair & Company
32
William Blair & Company
Illinois
$111M -$3.98M -10,092 -4%
JSP
33
Jackson Square Partners
California
$108M -$11M -27,798 -10%
TCIM
34
TIAA CREF Investment Management
New York
$105M +$21.2M +53,671 +30%
GGHC
35
Gilder Gagnon Howe & Co
New York
$95.2M +$5.79M +14,681 +7%
Morgan Stanley
36
Morgan Stanley
New York
$94M -$3.19M -8,104 -4%
1832 Asset Management
37
1832 Asset Management
Ontario, Canada
$84.3M -$4.11M -10,427 -5%
Massachusetts Financial Services
38
Massachusetts Financial Services
Massachusetts
$79.7M +$13.5M +34,284 +24%
Citadel Advisors
39
Citadel Advisors
Florida
$79.6M +$51.2M +129,959 +276%
Victory Capital Management
40
Victory Capital Management
Texas
$78M +$15M +37,948 +28%
CIBC Private Wealth Group
41
CIBC Private Wealth Group
Georgia
$77.6M -$1.77M -4,485 -3%
Legal & General Group
42
Legal & General Group
United Kingdom
$75.2M +$41.2M +104,583 +167%
Charles Schwab
43
Charles Schwab
California
$73.5M -$20.7M -52,612 -24%
SIMG
44
Stephens Investment Management Group
Texas
$72.1M -$22.4M -56,735 -26%
Mitsubishi UFJ Trust & Banking
45
Mitsubishi UFJ Trust & Banking
Japan
$70.8M -$56M -142,026 -47%
Sumitomo Mitsui Trust Group
46
Sumitomo Mitsui Trust Group
Japan
$69.1M +$3.7M +9,393 +7%
BS
47
Banco Santander
Spain
$68.7M -$768K -1,947 -1%
HCM
48
Hitchwood Capital Management
New York
$67.5M +$59.1M +150,000 New
Dimensional Fund Advisors
49
Dimensional Fund Advisors
Texas
$65.1M +$695K +1,764 +1%
Neuberger Berman Group
50
Neuberger Berman Group
New York
$64.6M -$7.6M -19,275 -12%

ABMD Hedge Fund Activity: Q3 2018 in Review

529 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Abiomed Inc (ABMD) for Q3 2018, worth a combined $17.9B — up 12% from $16B a quarter earlier.

Buyers outnumbered sellers: 71 funds opened new ABMD positions and 63 closed out — a net gain of 8 holders — while 202 added to existing stakes and 184 trimmed.

The largest buyer was AQR Capital Management, adding an estimated $314M. The largest seller was Baillie Gifford & Co, cutting an estimated $513M.

  • 529 institutional investors held Abiomed Inc (ABMD) as of Q3 2018, up from 527 in Q2 2018.
  • Funds reported $17.9B of Abiomed Inc stock for Q3 2018, up 12% quarter-over-quarter.
  • 71 funds opened new Abiomed Inc positions in Q3 2018 and 63 closed out, a net change of +8 holders.
  • The largest Abiomed Inc buyer in Q3 2018 was AQR Capital Management, an estimated $314M added.
  • The largest Abiomed Inc seller in Q3 2018 was Baillie Gifford & Co, an estimated $513M sold.

Based on aggregated 13F filings for Q3 2018.